Literature DB >> 18405841

Kinases as drug targets in the treatment of bipolar disorder.

Lisa A Catapano1, Husseini K Manji.   

Abstract

Bipolar disorder is one of the most severely debilitating of all medical illnesses, and is increasingly recognized as a major public health problem. For many patients with bipolar disorder, current pharmacotherapy is insufficient. Exciting recent data suggest that regulation of signaling molecules may be involved in the pathophysiology of the disorder, and in the mechanisms of action of mood stabilizers and antidepressants. Through our developing understanding of the biochemical targets of effective medications, several potential targets for new therapies have emerged. This short review will focus on two of the most promising such targets: glycogen synthase-3 and protein kinase C.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405841     DOI: 10.1016/j.drudis.2008.02.007

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  11 in total

1.  Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level.

Authors:  Elisabeth Barbier; Jia Bei Wang
Journal:  BMC Neurosci       Date:  2009-11-13       Impact factor: 3.288

Review 2.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

3.  Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study.

Authors:  Ayşegül Yildiz; Burç Aydin; Necati Gökmen; Ayşegül Yurt; Bruce Cohen; Pembe Keskinoglu; Dost Öngür; Perry Renshaw
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-03

4.  Effect of variation in diacylglycerol kinase η (DGKH) gene on brain function in a cohort at familial risk of bipolar disorder.

Authors:  Heather C Whalley; Martina Papmeyer; Liana Romaniuk; Eve C Johnstone; Jeremy Hall; Stephen M Lawrie; Jessika E Sussmann; Andrew M McIntosh
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

Review 5.  Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays.

Authors:  Marcela Cristina de Moraes; Carmen Lucia Cardoso; Cláudia Seidl; Ruin Moaddel; Quezia Bezerra Cass
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.

Authors:  Laura Caberlotto; Lucia Carboni; Floriana Zanderigo; Filippo Andreetta; Michela Andreoli; Gabriella Gentile; Maria Razzoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-22       Impact factor: 3.000

7.  Fragment screening of cyclin G-associated kinase by weak affinity chromatography.

Authors:  Elinor Meiby; Stefan Knapp; Jonathan M Elkins; Sten Ohlson
Journal:  Anal Bioanal Chem       Date:  2012-08-24       Impact factor: 4.142

Review 8.  Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery.

Authors:  Valère Lounnas; Tina Ritschel; Jan Kelder; Ross McGuire; Robert P Bywater; Nicolas Foloppe
Journal:  Comput Struct Biotechnol J       Date:  2013-04-02       Impact factor: 7.271

Review 10.  Implications and limitations of cellular reprogramming for psychiatric drug development.

Authors:  Brian T D Tobe; Michael G Brandel; Jeffrey S Nye; Evan Y Snyder
Journal:  Exp Mol Med       Date:  2013-11-15       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.